Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate cancer. However, despite initial responses, almost all men eventually develop castration refractory metastatic prostate cancer (CRPC) and die of their disease. Over the l...
Saved in:
| Main Authors: | Jesal C. Patel, Benjamin L. Maughan, Archana M. Agarwal, Julia A. Batten, Tian Y. Zhang, Neeraj Agarwal |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2013/981684 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THERAPY WITH SOMATOSTATIN ANALOGUES IN PATIENTS WITH CASTRATION-REFRACTORY PROSTATE CANCER
by: K. Y. Kanukoev, et al.
Published: (2015-04-01) -
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
by: Alexander W Wyatt, et al.
Published: (2015-04-01) -
Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
by: Masayoshi Zaitsu, et al.
Published: (2012-01-01) -
RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01) -
PREVENTION OF COMPLICATIONS IN CASTRATE-REFRACTORY PROSTATE CANCER PATIENTS WITH BONE METASTASES
by: K. M. Nushko, et al.
Published: (2015-10-01)